期刊文献+

缬沙坦对自发性高血压大鼠血压和肾素-血管紧张素水平的对照研究 被引量:2

Role of valsartan on blood pressure and renin-angiotensin of spontaneously hypertensive rats
下载PDF
导出
摘要 目的:动物实验观察缬沙坦的降压效果及其对血浆肾素活性和血管紧张素Ⅱ的影响。方法:24只雄性14周龄的SHR分为生理盐水组、苯那普利组、小剂量缬沙坦和大剂量缬沙坦组,另用6只同龄雄性WKY大鼠对照。观察用药4周前后的血压、肾素活性和血管紧张素对水平。结果:与生理盐水组、苯那普利组比较,缬沙坦的降压效果明确;大剂量缬沙坦平均下降 41. 7±4. 93 mmHg,明显大于小剂量组的降压幅度 27. 7±4. 46 mmHg,(P<0.01)。 SHR与WKY大鼠比较,血浆肾素活性仅在大剂量缬沙坦组明显升高;血管紧张素Ⅱ水平,大剂量缬沙坦组更为明显升高,而苯那普利组有所下降。结论:缬沙坦的降压效果优于苯那普利,苯那普利使血浆AngⅡ水平减低,而缬沙坦使血浆AngⅡ水平升高。在长期用药过程中,较高的血浆 Ang Ⅱ水平对人体的影响或对器官的影响如何,尚待进一步研究。 Aim: To investigate the effect of valsartan on blood pressure and renin-angiotensin system in plasma of spontaneously hypertensive rat (SHR). Methods: 24 14-week old male SHR and copared with 6 agematched male Wistar-Kyoto rats (WKY). SHR were dicided into fourgroups (each group,n = 6), respectively fed with NS, benazepril (1 mg/kg per day), valsartan (8 mg/kg per day), valsartan (24 mg/kg per day) for 4 weeks. The systolis blood pressure(SBP) was determines by the tail-cuff method. Renin activity and angiotensin Ⅱ (Ang Ⅱ ) level in plasma were measurred by radio-immunoassay. Results:Benazepril and valsartan were lowering blood pessure significantly. 8 mg/kg per day valsartan decreased SBP by 18%, and benazepril doses of 1 mg/kg per day, by 24%, while 24 mg/kg per day valsartan can decreased 30% of blood pressure. Plasma renin activity elevated in benazepril group and valsartan groups. The level of Aug Ⅱ were higher in SHR than in WKY (P< 0. 05 ). There were significantly elevation in valsartan groups than benazepril group Conclusion:Valsartan had significantly effect on BP. Simultaneously, valsartan elevatd level of plasma Ang Ⅱ, but renin actiivity only changed in a little.
出处 《高血压杂志》 CSCD 2000年第1期91-93,共3页 Chinese Journal of Hypertension
关键词 高血压 缬沙坦 血压 血管紧张素 hypertensions SHR Angiotensin Ⅱ angiotensin Ⅱ receptor antagonist
  • 相关文献

参考文献8

  • 1Urata H,etal.Chymase-dependent angiotension II forming systemsin humans[].American Journal of Hypertension.1996
  • 2Goodfriend TL,et al.Angiotensin receptors and their antagonist[].The New England Journal of Medicine.1996
  • 3Dzau VJ. et al.Tissue angiotension system in cardiovascularmedicine: a paradigm shift?[].Circulation.1994
  • 4Kathy K,et al.Molecular biology of the renin--angiotensin system[].Circulation.1993
  • 5Timmermans P,PC,et al.Angiotersin II receptors and angiotensinII receptor antagonist[].Pharmacology Reviews.1993
  • 6Nolson E,et al.Efficacy and safty of oral HK 954(Dup 753) ;anangiotensin receptor antagonist ; in essential Hypertension[].Journal of Hypertension.1991
  • 7EggenaP,BaretJD.Regulationandfunctionalconsequencesofangiotensinogengeneexpression[].Journal of Hypertension.1992
  • 8Suzuk J,Matsubara H,Urakami M.Rat angiotensinⅡ(type1A)receptor mRNA regulation and subtype expressionn in myocardial growth and hypertrophy[].Circulation Research.1993

同被引文献19

  • 1秦冬梅,许玉华,张华.皱叶酸模总黄酮和多糖的超声提取及含量测定[J].中国民族医药杂志,2004,10(3):33-34. 被引量:8
  • 2黄至斌,伍卫,韦育林,方昶,邓义军.自发高血压大鼠心肌肥厚与心室颤动阈值的关系[J].中山大学学报(医学科学版),2006,27(1):76-79. 被引量:9
  • 3孙莉,李树青.高血压致左室肥厚的发生机制及其治疗进展[J].中国心血管病研究,2007,5(4):315-317. 被引量:16
  • 4卢永昕.高血压:从左室肥厚到心力衰竭[J].中华高血压杂志,2007,15(3):189-191. 被引量:49
  • 5Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. J Hypertens, 2007,25(6) :1 105.
  • 6Akashiba A, Ono H, Ono Y, et al. Valsartan improves 1-NAME-exacerbated cardiac fibrosis with TGF-beta inhibition and apoptosis induction in spontaneously hypertensive rats[J]. J Cardiol, 2008, 52 (3) :239.
  • 7Rubulis A, Jensen J, Lundahl G, et al. Ischemia induces aggravation of baseline repolarization abnormalities in left ventricular hypertrophy : a deleterious interaction [ J ]. 2006,101 ( 1 ) : 102.
  • 8Wachtell K, Okin PM, Olsen MH, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study[J]. Circulation, 2007, 116(7) : 700.
  • 9Kahan T, Bergfeldt L. Left ventricular hypertrophy in hypertension: its arrhythmogenic potential[ J ]. Heart, 2005,91 (2) :250.
  • 10Alberte C, Zipes DP. Use of nonantiarrhythmic drugs for prevention of sudden cardiac death[ J]. J Cardiovasc Electrophysiol, 2003,14 (9 Suppl) :S87.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部